<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Interactive diabetes case 19: Pain and dysesthesias of the lower extremities in a 29-year-old patient with type 1 diabetes (distal sensory neuropathy) – B2
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Interactive diabetes case 19: Pain and dysesthesias of the lower extremities in a 29-year-old patient with type 1 diabetes (distal sensory neuropathy) – B2
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Interactive diabetes case 19: Pain and dysesthesias of the lower extremities in a 29-year-old patient with type 1 diabetes (distal sensory neuropathy) – B2
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lloyd Axelrod, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          ANSWER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Correct.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          Pregabalin
         </a>
         is an effective and easy-to-use agent for the treatment of painful diabetic neuropathy. It decreases insomnia and has positive effects on mood and quality of life. The absorption and bioavailability are independent of dose (in contrast to
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         , with which bioavailability decreases with increasing doses). The maximal plasma concentration and the area under the curve are proportional to dose. Steady-state concentrations are achieved in one to two days after repeated dosing. Pregabalin does not affect urine flow or cause urinary retention.
        </p>
        <p>
         The median time to onset of sustained improvement is four days with a dose of 600 mg a day, five days with 300 mg a day, 13 days with 150 mg a day, and 60 days with placebo [
         <a href="#rid1">
          1
         </a>
         ]. Doses above 300 mg a day are not recommended.
        </p>
        <p>
         Adverse effects include angioedema and other hypersensitivity reactions, dizziness, somnolence, dry mouth, peripheral edema, blurred vision, weight gain, and difficulty with concentration. Rarely, as with other antiepileptic agents,
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         may cause suicidal thoughts or behavior or changes in mood or behavior.
        </p>
        <p>
         The choice of agent for the treatment of painful diabetic neuropathy is often governed by the comorbidities and relative contraindications present. In this patient with symptoms of bladder outlet obstruction,
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         is preferable to a tricyclic.
        </p>
        <p>
         The management of the patients in this case is discussed further in the comment card. (See
         <a class="medical medical_answer" href="/z/d/html/4271.html" rel="external">
          "Interactive diabetes case 19: Pain and dysesthesias of the lower extremities in a 29-year-old patient with type 1 diabetes (distal sensory neuropathy) – Comment"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008; 31:1448.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4269 Version 10.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18356405" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
